The Drug Enforcement Administration has received two separate applications from companies seeking federal authorization to import marijuana-related controlled substances, according to notices scheduled to be published in the Federal Register on June 30.

In one filing, the United States Pharmacopeial Convention applied to be registered as an importer of marijuana and marijuana extract, both of which remain listed as Schedule I substances under federal law. The organization said it plans to import the substances for distribution as analytical reference standards to customers conducting analytical testing of raw materials.

The filing states that no other activities involving those drug codes would be authorized under the registration. DEA also noted that any approval would not extend to the importation of FDA-approved or non-approved finished dosage forms for commercial sale.

In a separate filing, Veterans Pharmaceuticals, Inc., based in Temecula, California, applied to import several controlled substances, including marijuana extract, marijuana and tetrahydrocannabinols. The application also includes substances such as psilocybin, psilocyn, DMT, LSD and methamphetamine.

According to DEA, Veterans Pharmaceuticals plans to import the listed substances to support research and clinical trials. As with the Pharmacopeial Convention application, DEA said the registration would not authorize other activities for the listed drug codes and would not allow importation of finished dosage forms for commercial sale.

The notices are applications, not final approvals. Registered bulk manufacturers of the affected substances and other eligible applicants may submit comments or objections, or request a hearing, within 30 days of publication in the Federal Register.

The filings come as federal marijuana policy remains in a period of significant change, with DEA proceedings on broader cannabis rescheduling continuing separately. While the applications do not alter marijuana’s federal status, they underscore the ongoing demand for federally compliant access to marijuana, marijuana extracts and THC for research, clinical trials and laboratory testing.